Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP3K12 | Q12852 | 18/20 | 0.62 |
| ▸ | SYK | P43405 | 1/20 | 0.47 |
| ▸ | IRAK1 | P51617 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16220047 | 0.89 | MAP3K12 (0.78) | MAP3K12 | |
| SCHEMBL16220162 | 0.86 | MAP3K12 (0.75) | MAP3K12 | |
| SCHEMBL16220223 | 0.85 | MAP3K12 (0.71) | MAP3K12SYK | |
| SCHEMBL16220060 | 0.84 | MAP3K12 (0.61) | MAP3K12 | |
| SCHEMBL17507061 | 0.84 | MAP3K12 (0.59) | MAP3K12SYK | |
| SCHEMBL16220322 | 0.82 | MAP3K12 (0.68) | MAP3K12 | |
| SCHEMBL16220455 | 0.80 | MAP3K12 (0.84) | MAP3K12 | |
| SCHEMBL16220320 | 0.78 | CHEK1 (0.53) | MAP3K12 | |
| SCHEMBL16220387 | 0.77 | MAP3K12 (1.00) | MAP3K12 | |
| SCHEMBL16220154 | 0.76 | MAP3K12 (0.61) | MAP3K12SYK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9868720-B2 | C-linked heterocycloaklyl substituted pyrimidines and their uses | GENENTECH, INC. (US) | 2018-01-16 | — | — | US | disclosed |
| US-9868720-B2 | C-linked heterocycloaklyl substituted pyrimidines and their uses | GENENTECH, INC. (US) | 2018-01-16 | — | — | US | disclosed |
| US-9868720-B2 | C-linked heterocycloaklyl substituted pyrimidines and their uses | GENENTECH, INC. (US) | 2018-01-16 | — | — | US | disclosed |
| US-20160046608-A1 | C-Linked Heterocycloaklyl Substituted Pyrimidines and their uses | GENENTECH, INC. (US) | 2016-02-18 | — | — | US | disclosed |
| US-20160046608-A1 | C-Linked Heterocycloaklyl Substituted Pyrimidines and their uses | GENENTECH, INC. (US) | 2016-02-18 | — | — | US | disclosed |
| US-20160046608-A1 | C-Linked Heterocycloaklyl Substituted Pyrimidines and their uses | GENENTECH, INC. (US) | 2016-02-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160046608-A1 | C-Linked Heterocycloaklyl Substituted Pyrimidines and their uses | TYMS, DPYD, TYMP | MAP3K12 1825/4885SYK 2556/4885IRAK1 1234/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.